Upstream Bio (UPB) Net Income towards Common Stockholders (2023 - 2025)

Upstream Bio has reported Net Income towards Common Stockholders over the past 3 years, most recently at -$42.5 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$42.5 million for Q4 2025, down 94.86% from a year ago — trailing twelve months through Dec 2025 was -$143.4 million (down 87.76% YoY), and the annual figure for FY2025 was -$143.4 million, down 87.76%.
  • Net Income towards Common Stockholders for Q4 2025 was -$42.5 million at Upstream Bio, down from -$33.7 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for UPB hit a ceiling of -$6.3 million in Q3 2023 and a floor of -$42.5 million in Q4 2025.
  • Median Net Income towards Common Stockholders over the past 3 years was -$21.4 million (2024), compared with a mean of -$24.1 million.
  • Peak annual rise in Net Income towards Common Stockholders hit 45.42% in 2024, while the deepest fall reached 236.37% in 2024.
  • Upstream Bio's Net Income towards Common Stockholders stood at -$15.0 million in 2023, then plummeted by 45.42% to -$21.8 million in 2024, then crashed by 94.86% to -$42.5 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$42.5 million (Q4 2025), -$33.7 million (Q3 2025), and -$40.0 million (Q2 2025) per Business Quant data.